Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Perioperative Ischemic Evaluation-3 Tril (POISE-3) KAIMRC Ongoing tranexamic acid 3 CT18/008/J King Abdulaziz Medical City NG (Riyadh)
"Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation " Novartis Ongoing deferasirox 2 CICL670FIC05 KAUH-J
OPEN LABEL, RANDOMIZED, SINGLE SITE CLINICAL TRIAL TO COMPARE THE SAFETY & EFFICACY OF HERBAL MELANIN EXTRACTED FROM NIGELLA SATIVA SEEDS VS STANDARD OF CARE TREATMENT IN TREATING GASTRITIS PATIENTS KAIMRC Rejected Melanole NIGELLA SATIVA 2 RC15/152/R NGHA-R
Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI) AstraZeneca Completed Osimertinib (AZD9291) 3 D5160C00022 KFSH
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study. Onxeo Completed Doxorubicin 3 BA2011/03/04 KAUH-J
Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy Roche Completed Tocilzumab 3b MA21573 KFSH & RC-J
Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant ICR Group - International Cancer Research group Ongoing palbociclib fulvestrant 3 ICRG 1201 KKUH
"Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients with Sickle Cell Disease or Other Anemias" ApoPharma Ongoing Deferiprone 3b LA38-EXT ACH
Lessening Organ Dysfunction with VITamin C KAIMRC Completed ascorbic acid injection 3 CT19/022/R King Abdulaziz Medical City NG (Riyadh)
Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients: Prospective Randomized Control trial King Fahad Hospital of the University Completed Ketamine 3 2016-01-042 -Version 02 KFUH
View 221 - 230 From 741